A (0:00)

Welcome to Pharma Daily's Week in Review for October 24, 2025. This week, from October 20 to October 24, we covered five major developments in the pharmaceutical and biotech industries. Let's take a look back at the most important stories that shaped our industry this week. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into a series of significant events that are shaping the future of drug development and patient care, starting with Merck kgaa. Their decision to close the active pharmaceutical ingredient plant in Arklow, Ireland by 2028 marks a pivotal shift in their manufacturing strategy. This move follows a strategic review and is emblematic of broader industry trends where companies reassess their operational strategies for greater efficiency. While this decision may impact the local workforce and supply chain dynamics, it underscores a wider re evaluation within the industry regarding sourcing strategies and optimizing production capabilities. Turning to regulatory news, Amgen and AstraZeneca have achieved a notable milestone with Tesspire, which has received approval for a second indication in both the US and Europe. This success highlights the strategic importance of expanding drug indications to maximize therapeutic potential and market reach. The approval also reflects a trend where robust clinical data supports regulatory endorsements across various regions, enhancing the global footprint of pharmaceutical innovations in manufacturing developments. Galderma is making headlines with a $650 million investment in US based production facilities for Nemluvl. This commitment to domestic manufacturing aligns with industry wide movements towards reshoring production to bolster supply chain resilience as demand for dermatological products increases, enhancing local infrastructure promises not only to meet market needs but also to secure supply stability in uncertain times. Meanwhile, Moderna's recent decision to discontinue its congenital cytomegalovirus vaccine program after disappointing phase three results illustrates the inherent uncertainties present in vaccine development. Despite extensive efforts, the vaccine did not demonstrate sufficient efficacy in preventing CMV infections among women. This outcome serves as a reminder of the critical role that robust clinical trial data plays in guiding strategic decisions within pharmaceutical pipelines. While MRNA technology has seen success against COVID 19, this setback highlights complexities involved when tackling other viral pathogens, potentially redirecting Moderna's focus towards more promising candidates. Roche is navigating through challenges such as currency fluctuations and slower than expected pharmaceutical sales in its third quarter. Despite these headwinds, Roche projects confidence in its long term growth strategies, showcasing resilience through its diversified portfolio. Furthermore, RoC's decision to discontinue five Chugai solid tumor assets reflects broader industry movements towards reassessment and realignment within pipelines. Such decisions often emerge from early phase trials failing to meet expected outcomes or shifts towards areas with greater promise, enabling companies like Roche to streamline resources towards more viable therapeutic areas. Compliance remains under scrutiny at Nephron Pharmaceuticals as ongoing FDA issues emphasize the necessity of maintaining stringent quality standards throughout manufacturing processes. Such regulatory challenges highlight the criticality of ensuring product safety and efficacy within the industry. On the technological front, the integration of artificial intelligence into life sciences commercialization is transforming industry landscapes. Though many organizations are still catching up with this digital shift, those that have embraced AI are experiencing significant improvements in efficiency and patient engagement as companies continue embedding AI into their strategic frameworks. These initiatives promise to redefine operational paradigms and open new paths for the landscape remains dynamic, characterized by strategic realignments and technological advancements. These changes pave the way for significant implications on drug development processes and patient care outcomes as companies adapt to emerging challenges and opportunities. Regeneron's choice to halt development on a CAR t candidate acquired from 270exemplifies another instance of cutting losses early in the process. Despite the potential of CAR T therapies for hematologic malignancies, this particular candidate didn't progress as hoped, illustrating risks inherent in advanced therapeutic developments. Arcturus therapeutics faced setbacks when interim data revealed their inhaled MRNA therapy for cystic fibrosis lacked efficacy. This outcome not only impacted Arcturus stock value but also underlined financial risks associated with biotech investments. Amidst these challenges, the resilience demonstrated across the industry is driven not only by innovation but by adaptive strategies addressing complex healthcare challenges, effectively leveraging technological advances. On a positive note, Ventix Biosciences reported encouraging results from their cardiovascular drug trials showing an 80% reduction in a key biomarker tied to stroke and cardiovascular risk within just one week of treatment during phase two studies. These findings offer hope for early intervention options in cardiovascular diseases that could improve patient outcomes significantly should later trials prove successful in scientific advancements. Nobel laureate Shimon Sakaguchi's work on converting rogue T cells into regulatory T cells presents groundbreaking potential for autoimmune diseases by offering personalized strategies rather than symptomatic treatments alone. Despite these advancements, roc's diagnostics business continues facing pressure due to pricing regulations in China, an example illustrating how external economic factors can influence company performance globally. Overall, these recent developments highlight both volatility and potential within pharma biotech sectors, underscoring importance placed upon strategic flexibility alongside robust scientific inquiry as adaptive management strategies navigate high risk yet rewarding environments driving transformative impacts on future patient care alongside drug development innovations. Looking at acquisitions shaping today's landscape Further, Roche maintains momentum through continued deal making activity evidenced during its Q3 earnings call following major acquisitions including 89Bio, valued at $3.5 billion plus Genentech partnering up with Orionis Biosciences under $2.1 billion agreement focused primarily around molecular glue technologies designed specifically enhancing therapeutic options available across varied domains strategically bolstering portfolios novel technology integrations ultimately advancing medicine significantly beyond current capabilities alone Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal changes and innovations shaping the industry landscape. Let's begin with a significant acquisition that is resonating across the sector. Alcaremaze has strategically acquired Avidel Pharmaceuticals for a noteworthy $2.1 billion. This acquisition is primarily aimed at Avidel's long acting narcolepsy drug Lumrez. This move not only acts as a growth catalyst for Alkermaze, but also strategically positions the company to potentially advance its own narcolepsy candidate, Alexor Exton. This acquisition highlights a broader trend within the industry, a shift towards consolidation and specialization in niche therapeutic areas, reflecting the ongoing strategic maneuvering within the pharmaceutical sector to enhance therapeutic portfolios in regulatory developments. There is an ongoing discussion around FDA cancer drug policies that's gaining attention. Eli Lilly's oncology president has highlighted the need for clearer regulatory pathways. The debate revolves around whether to prioritize survival metrics without crossover incentives or encourage U.S. participation through crossover designs. This underscores a tension between maintaining regulatory rigor and offering flexibility in clinical trial design, a balance that impacts how quickly new oncology therapies can reach patients. Turning to international trade, there are significant movements as the Trump administration initiates a probe under Section 301 of the Trade act of 1974. The aim is to assess if foreign nations are contributing their fair share to drug costs. Such an investigation could lead to tariffs potentially altering global pharmaceutical trade dynamics and influencing international pricing strategies. Reports suggest that former President Donald Trump is exploring strategies to impose tariffs on US Trading partners not adequately compensating for pharmaceuticals, reflecting ongoing tensions regarding international drug pricing. Technology is revolutionizing life science's commercialization strategies, with AI playing a pivotal role. Despite many organizations not being fully prepared for this digital shift. Companies like Real Chemistry are pioneering AI applications to navigate regulatory complexities such as FDA marketing compliance. This digital transformation is set to redefine how pharmaceutical companies engage with patients and healthcare providers, enhancing efficiency and compliance. In legal news, Regeneron has settled a patent dispute with Celltrien over ilea, allowing for the launch of a biosimilar by the end of 2026. This settlement is part of the growing biosimilars market, which offers cost effective alternatives to high priced biologics and enhances patient access to essential therapies. The industry's focus on oncology is further exemplified by Takeda's $1.2 billion upfront payment to Innovent Biologics for Cancer assets. This deal includes substantial milestone payments, marking oncology as a key growth area post NTVO era and highlighting the high stakes associated with breakthrough cancer therapies. Continuing with significant industry maneuvers, Takeda Pharmaceuticals has announced a potential investment up to $11.4 billion to acquire three antibody drug conjugates from Innovent Biologics. This deal includes an upfront payment of $1.2 billion and up to $10.2 billion in milestone payments, highlighting Takeda's commitment to expanding its oncology portfolio with innovative therapies that promise enhanced treatment outcomes for cancer patients. Ipsen's acquisition of AimCheck Therapeutics for $1.6 billion further emphasizes this focus on novel cancer treatments. The move includes ImCheck's mid stage leukemia monoclonal antibody ICT01, an asset aimed at acute myeloid leukemia, indicating Ibsen's strategic push into oncology by complementing its existing pipeline with assets targeted at infectious diseases and other oncology indications. At the recent European Society for Medical Oncology conference in Berlin, major biopharmaceutical companies like Pfizer, Merck, AstraZeneca and Bristol Myers Squibb showcased significant advancements in cancer therapeutics. These include antibody drug conjugates, bispecific antibodies and kinase inhibitors, modalities demonstrating robust efficacy and safety profiles across various cancer types. Meanwhile, Turns Pharmaceuticals has decided to discontinue its obesity program after disappointing phase two results, a reminder of the challenges inherent in developing effective metabolic treatments amidst rising expectations around clinical outcomes. The biotech market shows signs of recovery after recent downturns. However, experts caution against premature optimism regarding a full fledged comeback. Emphasizing AI's role as both tool and partner in drug development highlights the industry's focus on innovative methods enhancing R and D efficiency. These scientific advancements and strategic business moves underscore a commitment toward innovation while navigating evolving regulatory landscapes. The continued emphasis on cutting edge technologies like ADCs poised to significantly impact patient care Offering targeted treatment options Improved clinical outcomes as therapies progress through trials toward regulatory approval holding promise Reshaping treatment paradigms across therapeutic areas in conclusion, these dynamic times within the pharmaceutical biotech industries are characterized by rapid innovation, strategic partnerships, evolving regulatory landscapes and profound implications for patient care. Promising improved outcomes and advances in AI and biotechnology are paving the way for personalized and efficient treatment modalities. The future looks promising as the industry continues to push boundaries addressing complex health challenges globally. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we're diving into some of the most significant shifts occurring in these industries, touching on strategic restructuring, regulatory milestones and groundbreaking scientific advancements that are shaping the future of drug development and patient care. Let's begin with a major corporate shakeup at Novo Nordisk. The company has announced a significant leadership transition as former CEO Lars Reben Sorensen is set to become the new Chairman of the Board. This change follows the resignation of seven board members and indicates a strategic realignment within the company. The Novo Foundation's involvement suggests a deeper strategic shift, potentially aligning with new organizational objectives and innovations. Such moves are pivotal as they could influence Novo Nordisk's market position and future product development. Turning to scientific breakthroughs, Merck's collaboration with Kellin Biotech has yielded promising results with their TROP2 antibody drug conjugate. This ADC has shown success in two phase three trials targeting lung and breast cancers, underscoring the therapeutic potential of ADCs in oncology. By selectively targeting cancer cells while minimizing damage to healthy tissues, ADCs could significantly improve patient outcomes and represent a powerful modality in cancer treatment. In regulatory affairs, Kenvue is challenging the FDA over proposed safety warnings for Tylenol linked to autism during pregnancy. This dispute highlights the ongoing debates surrounding drug safety and regulatory oversight. The outcome could have significant implications for labeling practices in consumer trust in over the counter medications. Meanwhile, Summit Therapeutics plans to file for FDA approval of evansimab, highlighting ongoing innovation in drug development pipelines. Similarly, Novo Nordisk's semaglutide pill Rybelsis has received FDA expansion approval to reduce major adverse cardiovascular events. This sets a new benchmark for oral metabolism drugs by demonstrating their potential beyond glycemic control to positively impact cardiovascular health. As we explore industry trends, there's growing interest in direct to consumer drug sales. While this approach offers patients access to medications at reduced costs, it raises concerns about privacy and the quality of care without traditional healthcare provider interactions. Additionally, a notable decline in pharmaceutical TV ad spending by 19% in Q3 suggests a shift towards digital engagement strategies. Amidst these narratives, the Biotechnology Innovation Organization has launched an awareness campaign to combat misinformation about vaccines. This effort underscores the importance of immunizations in public health and aims to reinforce trust amid rising disinformation. In another scientific advancement, GSK has released positive phase 3 data for Sparrow Therapeutics oral antibiotic candidates candidate the oral formulation's efficacy, comparable to intravenous options, could lead to broader use and improved patient adherence. Critical advancements as antibiotic resistance remains a global health challenge, investment activities reflect strategic shifts within the industry as well. CureWell Capital's investment in Wilmington PharmaTech aims to enhance US active pharmaceutical ingredient production capacity, a crucial step given recent global supply chain disruptions. Similarly, India's ACG is making a $200 million investment in its first US empty capsule production facility, highlighting the strategic importance of manufacturing capabilities on American soil. Galapagos decision to wind down its cell therapy unit marks a significant strategic pivot from its previous focus on this modality. This shift reflects broader industry trends where companies reassess priorities based on market dynamics and clinical trial outcomes. Now let's delve into roc's breakthrough with Goziva Obinutuzumab. Traditionally used as an anti cancer therapy, it has recently achieved FDA approval for lupus nephritis, marking its first non oncology indication. This opens new therapeutic avenues for autoimmune diseases by leveraging monoclonal antibodies to target specific immune pathways, potentially altering the treatment landscape for lupus nephritis. In ophthalmology, Glakos secured FDA approval for its epaoxicornial cross linking therapy aimed at treating keratoconus, a rare disorder, by strengthening corneal tissue through biochemical pathways. Epoxa provides a non invasive option that offers hope for improved patient outcomes. AstraZeneca is also making strides in treating lupus with its Cifnelo self injection pen for systemic lupus erythematosis. The European Medicines Agency's recommendation for approval enhances patient convenience and adherence by targeting type 1 interferon pathways. Recent clinical trials have showcased promising results across various cancer types as well as Johnson and Johnson's. Amivantamab demonstrated a 45% response rate in a phase 1b2 trial for recurrent head and neck cancer exelixis. Zanzolentinib showed improved outcomes in metastatic colorectal cancer patients, while Rox Tecentriq reduced death risk significantly in muscle invasive bladder cancer. These advancements highlight the potential of checkpoint inhibitors and targeted therapies to improve survival rates. However, not all trials meet their endpoints. Roc's Vamikeebert for uveitic macular edema and Euphoria's BNC210 for social anxiety disorder failed despite promising safety profiles. These challenges underscore the complexities inherent in drug development. Strategic movements continue shaping industry dynamics as rumors of Eli Lilly potentially acquiring Nectar therapeutics circulate, illustrating high stakes in acquiring innovative biotechnologies that enhance therapeutic pipelines. Funding activities remain robust, with substantial investments aimed at advancing drug development across various domains, reflecting confidence in emerging therapies poised to disrupt treatment paradigms. In summary, these developments reflect an industry characterized by significant scientific advancements alongside strategic realignments and regulatory milestones, each playing a crucial role in shaping future advances in patient care and therapeutic interventions. As companies navigate these complexities, their ability to innovate while maintaining operational agility will be crucial amid an increasingly competitive global market landscape. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments. One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody drug conjugate Datro Way demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head to head trial involving TROP2 targeted therapies. This reflects the increasing focus on antibody drug conjugates as precision medicine tools that offer targeted treatment options with potentially improved outcomes over traditional chemotherapy. In a move highlighting the ongoing trend of bolstering domestic production capacities, Merck is making a substantial $3 billion investment in a small molecule drug plant in Virginia. This is part of a broader $70 billion commitment to expand manufacturing and R and D capabilities in the U.S. such strategic investments are crucial for maintaining competitive advantage and ensuring drug availability while meeting rising demands and streamlining supply chains. Turning to regulatory updates, the FDA has Approved Amgen and AstraZeneca's TestSpire for chronic rhinosinusitis with N polyps. This marks TestSpire's second indication following its initial approval for severe asthma in 2021. The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent in Oncology, Merckx, Keytruda and Astellas Pfizer's pads have made headlines with compelling results in muscle invasive bladder cancer. The combination therapy reduced the risk of death by 50%, reinforcing Keytruda's position as a cornerstone immunotherapy across multiple cancer types. This result not only augments treatment options but also signifies the potential for combination regimens to enhance patient outcomes. Roche has expanded the indication of its aging oncology drug Goxiva to treat lupus nephritis, demonstrating strategic repurposing efforts to extend the lifecycle of existing therapies. While this expansion into autoimmune diseases comes late in Goziva's life cycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas. AstraZeneca and Daiichi Sankyozenhurtu showed robust efficacy in early breast cancer treatment, potentially reshaping therapeutic strategies by offering new hope for early intervention. Similarly, Novartis Pluvicto demonstrated promise in slowing hormone sensitive prostate cancer progression, underscoring the potential of radioligand therapies in oncology. However, not all developments have been positive. AstraZeneca faced setbacks when its Mfinzi and Lynparza combination failed to meet survival goals in ovarian cancer, underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the fda. The industry is also witnessing significant advancements in next generation ADCs, as evidenced by Tubulus's 59% response rate in early clinical trials, which has attracted substantial investor interest. Additionally, Grails Galleri Cancer Blood Test is progressing towards FDA review with enhanced performance data, potentially revolutionizing cancer screening and early detection practices. These scientific and regulatory milestones are complemented by strategic investments in bioconjugation technologies. Cohance Life Sciences $10 million investment in NJ Bio to enhance GMP bioconjugation capabilities exemplifies this trend. Such investments are crucial for advancing ADC development, which remains a focal point for innovative cancer therapies. Overall, these developments reflect a dynamic phase for the pharmaceutical and biotech sectors, characterized by significant scientific advancements, strategic investments in infrastructure and R and D, and an emphasis on expanding indications for existing drugs. These trends are poised to enhance patient care through more precise and effective treatment options while driving innovation in drug development. In other news from the pharmaceutical industry, Roche is marking its efforts in eye disease treatment with mixed results from their phase three trials. Despite not meeting the primary endpoint in one study, Roche plans to file for FDA approval regardless. This decision reflects a strategic emphasis on potential benefits indicated by secondary endpoints or overall clinical profile illustrating the complexities of drug development where regulatory strategies must balance imperfect data with clinical need. In oncology updates, Roche presented data on Giridestrant, an oral selective estrogen receptor degrader, which demonstrated a significant reduction in breast cancer progression risk by 62% for hormone receptor positive breast cancer patients. This development highlights sird's expanding role in breast cancer therapy, offering hope for improved outcomes. Antibody drug conjugates continue to be a focal point of innovation at conferences like Esmo Tubulus's Next generation ADC achieved impressive clinical outcomes, reinforcing investor interest. Meanwhile, Akeso and Summit Therapeutics EV onceumab outperformed standard PD1 inhibitors combined with chemotherapy in first line non small cell lung cancer trials, marking significant strides forward within immunotherapy combinations. Exelixis reported promising data for Zanzolintinib, their franchise molecule, showing reduced death risk by 20% compared to Stavarga, positioning it as a potential new standard within targeted cancer therap. This indicates ongoing evolution toward more patient tailored treatments within oncology landscapes. Daiichi Sankyo, along with Merck's progress advancing their ovarian cancer into phase three, exemplifies how strategic collaborations drive advancements across treatment modalities. AstraZeneca's confidence within its ADC pipeline despite industry competition underscores importance proprietary innovation plays maintaining competitive advantages. Pfizer's ongoing research managing cancer related wasting conditions utilizing Pontegromab initially developed heart failure demonstrates drug repurposing potentials addressing complex syndromes, improving quality life among patients living with cancers today. Lastly, Avaxion's personalized vaccine achieved a 75% objective response in advanced melanoma, yet financial constraints led to a reduced trial scope. This highlights funding challenges impacting design execution in the biotech sector, although promising efficacy data could attract future partnerships and investment, furthering development efforts to ultimately benefit patients awaiting novel interventions. Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we'll delve into a series of remarkable advancements and strategic movements shaping the landscape of healthcare. Let's start with a recent spotlight on the European Society for Medical Oncology Congress 2025, where key clinical trial outcomes have emerged, potentially reshaping future treatment protocols. AstraZeneca made waves with its phase three trial results for Imfinzi, a PD L1 inhibitor, in high risk non muscle invasive bladder cancer. The findings suggest that Imfinzi stands strong against Pfizer's PD1 candidate, SusanLumab. This is particularly noteworthy as bladder cancer has historically had limited non invasive treatment options. The implications for patient care are substantial, providing hope for improved management of this form of cancer and possibly influencing treatment standards. Meanwhile, Eli Lilly's Verzenio marked another success at the ESMO Congress with its overall survival win in early breast cancer cases. This victory enhances Verzenio's standing within the CDK4.6 inhibitor class, suggesting increased adoption in clinical settings. The demonstration of extended survival benefits not only strengthens Verzenio's competitive position but also contributes to setting a new standard of care in early breast cancer treatment. On the regulatory front, Sanofi encountered mixed outcomes from the European Medicines Agency's Committee for Medicinal Products for Human Use, while Resuroc was not recommended as a third line treatment for chronic graft versus host disease. This decision underscores the stringent regulatory processes companies navigate despite existing market success in other regions like the us In a significant move by the FDA to expedite drug approvals, nine companies, including Merck, KGAA and Regeneron received priority review vouchers. These vouchers allow a shortened review timeline, reflecting an ongoing trend towards accelerating drug availability to address unmet medical needs swiftly. In terms of strategic developments, EMD Serrano Merck KGA's US branch has unveiled a major discount initiative for its IVF treatments on the Trump RX platform. This aligns with broader efforts to make fertility treatments more accessible amidst rising demand and economic pressures. The metabolic dysfunction associated steatohepatitis arena is also witnessing robust interest, with over $10 billion recently reported in mergers and acquisitions. This surge indicates confidence among Big Pharma players in MASH as a lucrative therapeutic field ripe for innovation and development in response to competitive pressures and operational challenges. Keysar Life Sciences is preparing for layoffs following the FDA's decision to cancel a critical meeting related to its R and D program. This situation illustrates the volatile dynamics within biotech firms where regulatory decisions can significantly impact corporate strategies and workforce stability. Overall, these developments reflect an industry characterized by rapid innovation, strategic realignments and an evolving regulatory framework. The implications for patient care are substantial as these scientific advancements promise enhanced treatment options across various therapeutic areas. Switching gears to scientific developments, Bristol Myers Squibb has reported promising results from early stage trials of its EGFRX HER3 antibody drug conjugate, demonstrating a 55% overall response rate. This positions BMS to potentially gain a competitive edge in the ADC market, a sector valued for targeting cancer cells while minimizing side effects on healthy tissues. Strategic partnerships continue to shape industry growth and innovation. Roche has secured a deal with Hansa Pharmaceutical worth up to $1.45 billion for global rights to an experimental ADC outside Greater China. Similarly, Rani Therapeutics has partnered with Chugai Pharmaceuticals in a deal valued at $1.09 billion to integrate its innovative drug delivery technology with Chugai's assets aimed at rare disease treatments. Kite Pharma has expanded its focus on CAR T therapies through a partnership with China's Pregine Biopharma, valued at $1.64 billion. This collaboration emphasizes Kait's strategic focus on advancing its CAR T capabilities, a key player in cancer immunotherapy due to their ability to reprogram patients immune cells to attack cancer cells. Geopolitical tensions have also been highlighted with Nakarta CEO Paul Hastings urging caution against imposing restrictions on Chinese scientific collaboration. Hastings argues such penalties could hinder progress and negatively affect patient care. Meanwhile, Astellas Pharma has opted out of its gene therapy pact with Tayshia gene therapies before launching pivotal trials for an Adeno associated virus based therapy targeting rare neurodevelopmental disorders, illustrating inherent uncertainties in gene therapy advancements. In an effort towards transparency, the FDA will now publicly release complete response letters upon issuance, a move that poses both risks and opportunities by potentially influencing investor perceptions and competitive dynamics. Industry restructuring continues as seen with Imab Biopharma undergoing comprehensive changes including a new name and strategy alongside plans for a Hong Kong ipo, all part of adaptive strategies in response to evolving market conditions. These stories underscore dynamic shifts within pharma and biotech driven by scientific innovation, strategic collaborations, regulatory changes and geopolitical factors, all having significant implications on accelerating availability of cutting edge therapies while navigating complex landscapes effectively turning our attention now towards dermatological therapeutics and oncology advancements, varadermics has raised $150 million in Series C funding aimed at advancing its hair regrowth pill through regulatory submissions, marking another substantial investment focused on hair regrowth within just one week. This effort highlights growing interest within dermatological therapeutics seeking effective solutions targeting hair loss conditions. You that concludes our Week in review for October24,2025, covering five episodes from October 20 to October24. Thank you for listening to Pharma Daily's Week in Review. Join us tomorrow for more breaking news and analysis from the pharmaceutical and biotech world.